Compare ARW & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARW | RDY |
|---|---|---|
| Founded | 1935 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 9.9B |
| IPO Year | 1994 | 2001 |
| Metric | ARW | RDY |
|---|---|---|
| Price | $192.83 | $14.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $216.25 | $14.43 |
| AVG Volume (30 Days) | 449.2K | ★ 2.7M |
| Earning Date | 11-05-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 0.44% |
| EPS Growth | ★ 49.93 | N/A |
| EPS | ★ 15.97 | N/A |
| Revenue | ★ $30,852,935,000.00 | N/A |
| Revenue This Year | $36.38 | $4.57 |
| Revenue Next Year | $13.01 | $11.92 |
| P/E Ratio | ★ $12.41 | $18.67 |
| Revenue Growth | ★ 10.49 | N/A |
| 52 Week Low | $101.79 | $11.36 |
| 52 Week High | $249.43 | $15.67 |
| Indicator | ARW | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 40.11 | 70.98 |
| Support Level | $176.42 | $12.91 |
| Resistance Level | $225.25 | $15.67 |
| Average True Range (ATR) | 9.96 | 0.27 |
| MACD | -0.89 | 0.02 |
| Stochastic Oscillator | 32.38 | 81.85 |
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the global components business and the global enterprise computing solutions.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.